Jaguar Health to Announce Pivotal Phase 3 OnTarget Trial Results by July 23, 2024

Jaguar Health, Inc. (NASDAQ:JAGX) will hold an investor webcast on or before July 23, 2024, to disclose the results of their pivotal phase 3 OnTarget trial of crofelemer. The trial focuses on preventing diarrhea in adult cancer patients receiving targeted therapy. The webcast will include updates on Jaguar’s cancer supportive care portfolio and feature contributions from the scientific team, patient advocates, and oncology experts.

Diarrhea affects up to 40% of cancer patients, often leading them to discontinue therapy. Oral mucositis, another common side effect, impacts about 40% of chemotherapy patients. This investor webcast is aimed at addressing these severe side effects, highlighting the potential benefits of crofelemer.

Additional topics to be discussed include Jaguar's U.S. in-license agreement for Gelclair®, a product for oral mucositis, and recent commercial agreements with Turkish company GEN. Jaguar’s advocacy programs and previous studies published in PLOS ONE regarding crofelemer will also be covered.

Jaguar President and CEO Lisa Conte expressed optimism about the trial’s results, emphasizing their importance for both the company and patients. Stacey Tinianov, an advocate, highlighted the critical need for supportive care during cancer treatment to maintain quality of life.